Emcure Pharmaceuticals announced robust financial results for the fiscal year ended March 31, 2026, achieving a major milestone by crossing $1 billion in annual revenue. The company reported a 16.6% year-over-year revenue growth for the full year and a 16.7% growth in the fourth quarter. Driven by strong international momentum and strategic acquisitions, Emcure also delivered 41% growth in adjusted PAT for the full year.
Full Year Financial Performance
For the fiscal year ending March 31, 2026, Emcure Pharmaceuticals achieved a consolidated revenue from operations of ₹9,204 crore, representing a 16.6% year-over-year increase. The company’s EBITDA for the year stood at ₹1,789 crore, up 21.8%, with EBITDA margins reaching 19.4%. The reported Profit After Tax (PAT) for the full year grew by 33.1% to ₹941 crore, while the adjusted PAT rose by 40.9% to ₹1,008 crore.
Fourth Quarter Highlights
In the final quarter (January – March 2026), Emcure reported revenue from operations of ₹2,470 crore, a 16.7% increase compared to the same period in the previous year. The quarter saw EBITDA of ₹485 crore with a margin of 19.7%. The reported PAT for the quarter was ₹244 crore, up 23.6%, and the adjusted PAT for the quarter grew by 36.0% to ₹279 crore.
Strategic Growth and Dividends
The company’s growth in FY26 was supported by a balanced performance across geographies. International business sales grew by 22.2% to ₹5,177 crore, while the domestic segment grew by 10.0% to ₹4,027 crore. In line with this performance, the Board of Directors has recommended a final dividend of ₹3.60 per equity share, subject to shareholder approval.
Leadership Re-appointments
Emcure also announced key leadership continuity to drive its future strategic plans. The Board approved the re-appointment of Dr. Mukund Gurjar as a Whole-time Director for a period of one year, effective August 28, 2026. Furthermore, Mr. Satish Mehta has been re-appointed as the Managing Director for a term of five years, effective April 01, 2027, both subject to shareholder approval at the upcoming Annual General Meeting.
Source: BSE
